LANTUS Drug Profile

Summary for Tradename: LANTUS

High Confidence Patents:	3
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for LANTUS
Recent Clinical Trials:	See clinical trials for LANTUS

See drug prices for LANTUS

Recent Clinical Trials for LANTUS

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Xentria, Inc.	PHASE1
University of Basrah	N/A
Hospital de Especialidades, Centro Medico Nacional "La Raza", Instituto Mexicano del Seguro Social	Phase 4

See all LANTUS clinical trials

Pharmacology for LANTUS

Established Pharmacologic Class	Insulin Analog
Chemical Structure	Insulin

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for LANTUS Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for LANTUS Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Sanofi-aventis U.s. Llc	LANTUS	insulin glargine	Injection	021081	5,370,629	2013-10-13	DrugPatentWatch analysis and company disclosures
Sanofi-aventis U.s. Llc	LANTUS	insulin glargine	Injection	021081	5,509,905	2013-10-13	DrugPatentWatch analysis and company disclosures
Sanofi-aventis U.s. Llc	LANTUS	insulin glargine	Injection	021081	5,656,722	2014-09-12	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for LANTUS Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Sanofi-aventis U.s. Llc	LANTUS	insulin glargine	Injection	021081	10,004,686	2033-06-12	Patent claims search
Sanofi-aventis U.s. Llc	LANTUS	insulin glargine	Injection	021081	10,016,338	2036-12-20	Patent claims search
Sanofi-aventis U.s. Llc	LANTUS	insulin glargine	Injection	021081	10,029,011	2030-11-11	Patent claims search

International Patents for LANTUS

Country	Patent Number	Estimated Expiration
Luxembourg	90614
Norway	177963
Australia	4441289

Supplementary Protection Certificates for LANTUS

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0091020-8 0090020-9	Sweden		PRODUCT NAME: LANTUS - INSULIN GLARGIN; REGISTRATION NO/DATE: EU/1/00/134/001 20000609
300883	Netherlands		PRODUCT NAME: INSULIN GLARGINE/LIXISENATIDE; REGISTRATION NO/DATE: EU/1/16/1157 20170113
C300019	Netherlands		PRODUCT NAME: INSULINE GLARGINE,DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH GESCHIKT ZOUT; REGISTRATION NO/DATE: EU/1/00/134/001 - 007 20000609

Market Dynamics and Financial Trajectory for LANTUS (Insulin Glargine)

Last updated: January 8, 2026

Executive Summary

LANTUS (insulin glargine) stands as a flagship long-acting insulin analog developed by Sanofi, dominating the basal insulin market since its introduction in 2000. Despite competitive pressures from biosimilars and oral alternatives, LANTUS has maintained substantial sales momentum. This analysis explores the evolving market landscape, competitive dynamics, revenue trajectory, regulatory influences, and strategic considerations shaping LANTUS's future. Its legacy market share, recent biosimilar entry, and pricing strategies will be examined alongside forecasts to aid stakeholders' decision-making.

---

What Are the Market Drivers for LANTUS?

Diabetes Prevalence and Market Demand

• The global diabetes population neared 537 million in 2021, projected to reach 643 million by 2030 (IDF Diabetes Atlas, 10th Ed.).
• The rising prevalence of type 1 and type 2 diabetes sustains high demand for basal insulin therapies like LANTUS.
• Increasing penetration in emerging markets enhances growth opportunities.

Therapeutic Landscape

• LANTUS’s long-acting profile has become standard-of-care for basal insulin management.
• Landmark studies (e.g., the ORIGIN trial) affirmed the safety and efficacy of insulin glargine.
• Competition from newer insulins (e.g., Tresiba, Basaglar) and non-insulin therapies impacts market share but sustains overall growth in the insulin segment.

Regulatory Environment and Policies

• Stringent regulatory pathways influence biosimilar and generic entry.
• Price control measures in markets such as Europe and potential payor pressure in the U.S. impact revenue.

Reimbursement and Pricing Dynamics

• Reimbursed pricing varies globally, with significant discounts in markets adopting healthcare austerity measures.
• Manufacturer strategies increasingly focus on value-based pricing and formulary placements.

---

How Has the Competitive Landscape Evolved?

Biosimilar Entry and Impact

• Basaglar (Eli Lilly / Boehringer Ingelheim) introduced as a biosimilar insulin glargine in 2016 in the U.S.
• European markets saw biosimilar launches shortly after, resulting in price reductions and volume shifts.
• Biosimilars have collectively eroded LANTUS's market share but have not wholly displaced it due to branding and trusted prescriber bases.

Market Share Trends

Year	LANTUS Market Share	Biosimilar Share	Total Insulin Glargine Market
2018	~80%	~20%	$4.2 billion
2020	~65%	~35%	$4.7 billion
2022*	~55%	~45%	$5.1 billion

*Estimates based on IQVIA and industry reports (2022).

Innovation and Route to Market

• Introduction of biosimilars and delivery device improvements influence prescribing habits.
• Low-concentration formulations and pen devices bolster patient adherence.

---

What Is the Revenue Trajectory of LANTUS?

Historical Revenue Overview

Year	Global Sales (USD billions)	Key Notes
2010	~$4.5	Peak sales; market leader
2015	~$4.2	Competitive pressure rising
2018	~$4.0	Biosimilar launches influence
2020	~$3.4	Continued biosimilar penetration; price erosion
2022*	~$3.2	Stabilization, market consolidation

*Estimated, based on industry analytics.

Forecasted Trends (2023-2028)

• CAGR of approximately -2% to -3% driven by biosimilar competition and pricing pressures.
• The total insulin glargine market expected to grow at 3-4% CAGR owing to increasing global diabetic populations.
• LANTUS's residual premium likely to diminish as biosimilars tighten price margins.

Revenue Outlook by Region

Region	2022 (USD millions)	Outlook	Key Drivers
North America	~$1,200	Slight decline; biosimilar penetration increases	Price, formulary decisions, insurance policies
Europe	~$800	Decline continues; emphasis on biosimilars	Healthcare policy shifts, generics uptake
Asia-Pacific	~$600	Growth potential, moderate biosimilar entry	Rising diabetes prevalence, market expansion
Emerging Markets	~$400	Significant growth; price-sensitive markets	Affordability, insulin access initiatives

---

What Are the Future Strategic Considerations for LANTUS?

Market Positioning Amid Biosimilar Competition

• Brand loyalty and physician preference remain vital. Sanofi emphasizes clinical data and device quality to sustain premium pricing.
• Portfolio diversification—LANTUS's successor, Toujeo (insulin glargine U300), offers more concentrated dosing with potentially higher margins.

Innovation and Lifecycle Management

• LANTUS’s patent expiry in many jurisdictions has led to biosimilar competition.
• Sanofi's strategic focus on adjunctive therapies (e.g., GLP-1 receptor agonists) complements insulin revenue streams.

Pricing and Reimbursement Strategies

• Negotiations with payers are increasingly crucial, especially in cost-containment environments.
• Adoption of value-based pricing models and outcomes-based agreements can offer competitive advantages.

Pipeline and Regulatory Pathways

• Long-term success may hinge on developing novel formulations, delivery systems, and expanding indications (e.g., prediabetes, pediatric populations).

---

Comparative Analysis with Competitors

Drug Name	Type	Introduction Year	Market Share (2022)	Price Position	Unique Features
LANTUS (Insulin Glargine)	Long-acting insulin	2000	~55%	Premium	Proven efficacy, trusted brand
Basaglar (biosimilar)	Biosimilar insulin glargine	2016	~35%	Lower	Cost-effective alternative
Tresiba (insulin degludec)	Ultra long-acting insulin	2015	~5%	Premium	Longer duration, lower hypoglycemia risk
Levemir (insulin detemir)	Long-acting insulin	2005	~5%	Mid-tier	Once or twice daily dosing

---

Deep-Dive into Regulatory and Policy Influences

• The European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) regulate biosimilar approvals, affecting market entry timelines.
• Cost containment policies in Europe (e.g., NHS negotiations) and increasing copayments in the U.S. influence prescribing behaviors and sales.
• Pharmacoeconomic evaluations increasingly favor biosimilars, pressuring brand-name drugs like LANTUS to justify premium pricing.

---

Key Takeaways

• Market saturation and biosimilar commoditization are reducing LANTUS's growth rate, with a projected decline in revenues of approximately 2-3% annually.
• Global diabetes epidemic sustains total insulin market growth; however, the share captured by LANTUS diminishes as biosimilar competition intensifies.
• Strategic focus should include innovation in device technology, expansion into emerging markets, and portfolio diversification.
• Pricing strategies need reevaluation within increasingly price-sensitive healthcare systems; value-based agreements may buffer revenue erosion.
• Regulatory landscape remains a key determinant of biosimilar success; timely approvals and market acceptance are critical.

---

FAQs

1. How has biosimilar entry impacted LANTUS’s market share?
Biosimilar insulin glargine products, notably Basaglar, introduced in the U.S. and Europe, have taken significant portions of the market, reducing LANTUS’s global share from around 80% in 2018 to approximately 55% in 2022. This has resulted in price competition and volume shifts, with expected further erosion as biosimilar access widens.

2. Will LANTUS remain profitable amid declining sales?
While overall revenues are declining, LANTUS remains a valuable brand due to physician trust and clinical efficacy. Profitability depends on manufacturing efficiencies, pricing strategies, and portfolio management, including the promotion of newer formulations like Toujeo.

3. What are the primary growth opportunities for LANTUS’s parent company?
Sanofi is leveraging biosimilar insulin glo r making and expanding key adjacent therapies such as GLP-1 receptor agonists (e.g., Ozempic). Additionally, emerging markets and personalized medicine are strategic areas to sustain revenues.

4. How do regulatory policies affect the availability of biosimilars?
Strict regulatory pathways, including bioequivalence and manufacturing standards, influence biosimilar approval timelines. In markets with streamlined approvals, biosimilars gain faster access, intensifying competition and affecting LANTUS sales.

5. What innovations could extend LANTUS’s market longevity?
Advancements in delivery devices, such as smart pens, and development of ultra-long-acting insulins or combination therapies (e.g., basal-bolus formulations), could reinforce LANTUS’s relevance. Moreover, digital health integrations improve adherence, maintaining therapeutic value.

---

Sources

1. International Diabetes Federation. Diabetes Atlas, 10th Ed. 2021.
2. IQVIA. Global Outlook on Diabetes Care Market, 2022.
3. FDA and EMA approvals and policy documents on biosimilars, 2016–2022.
4. Sanofi Annual Reports, 2010–2022.
5. Market Research Future. Insulin Market Trends, 2022.